Kevin B. Alton

Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663

Margaret van Heek, Constance Farley, Douglas S. Compton et al. · British Journal of Pharmacology · 2000 · 327 citations · Full text

In Vivo Metabolism-Based Discovery of a Potent Cholesterol Absorption Inhibitor, SCH58235, in the Rat and Rhesus Monkey through the Identification of the Active Metabolites of SCH48461

Margaret van Heek, Constance F. France, Douglas S. Compton et al. · Journal of Pharmacology and Experimental Therapeutics · 1997 · 305 citations

Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer.

Sharyn D. Baker, Mark Wirth, Paul Statkevich et al. · PubMed · 1999 · 225 citations

Pathology, Oral Administration, Whole Blood +20

IDENTIFICATION OF HUMAN UDP-GLUCURONOSYLTRANSFERASE ENZYME(S) RESPONSIBLE FOR THE GLUCURONIDATION OF POSACONAZOLE (NOXAFIL)

Anima Ghosal, Neil Hapangama, Yuan Yuan et al. · Drug Metabolism and Disposition · 2004 · 166 citations

Disposition of the Selective Cholesterol Absorption Inhibitor Ezetimibe in Healthy Male Subjects

James E. Patrick, Teddy Kosoglou, Kathe Stauber et al. · Drug Metabolism and Disposition · 2002 · 165 citations